Chronic dopaminergic signaling in the basal ganglia: A damage perspective on kinases and fos-related antigens

Addiction Biology

Volumn 5, Issue 3, 2000, Pages 369-376

  O'Callaghan, James P ^a,c   Miller, Diane B ^a   Pennypacker, Keith R ^b  

^a NATIONAL INSTITUTE FOR OCCUPATIONAL SAFETY AND HEALTH   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

^c NATIONAL INSTITUTE FOR OCCUPATIONAL SAFETY AND HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COCAINE; DOPAMINE; METHAMPHETAMINE; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHOPROTEIN DARPP 32; PSYCHOSTIMULANT AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; BASAL GANGLION; CONFERENCE PAPER; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; DOPAMINERGIC TRANSMISSION; DRUG DEPENDENCE; MOUSE; NERVE ENDING; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION;

EID: 0033909551     PISSN: 13556215     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1369-1600.2000.tb00204.x     Document Type: Conference Paper

References (56)

1. 1. Walaas SI, Greengard P. Protein phosphorylation and neuronal function. Pharmacol Rev 1991;43: 299-349.
2. 2. Nestler EJ, Aghajanian GK. Molecular and cellular basis of addiction. Science 1997;278:58-63.
3. 3. Nestler EJ. Hard target: understanding dopaminergic neurotransmission. Cell 1994;79:923-926.
4. 4. Nestler EJ. Molecular neurobiology of drug addiction. Neuropsychopharmacology 1994;11:77-87.
5. 5. Nestler EJ, Hope BT, Widnell KL. Drug addiction: a model for the molecular basis of neural plasticity. Neuron 1993;11:995-1006.
6. 6. Nestler EJ. Cellular responses to chronic treatment with drugs of abuse. Crit Rev Neurobiol 1993;7:23-39.
7. 7. Bowyer JF, Frame LT, Clausing P et al. Long-term effects of amphetamine neurotoxicity on tyrosine hydroxylase mRNA and protein in aged rats. J Pharmacol Exp Ther 1998;286:1074-85.
8. 8. O'Callaghan JP, Miller DB. Neurotoxicity profiles of substituted amphetamines in the C57BL/6J mouse. J Pharmacol Exp Ther 1994;270: 741-51.
9. 9. Koob GF, Nestler EJ. The neurobiology of drug addiction. J Neuropsychiatry Clin Neurosci 1997;9:482-97.
10. 10. Rocha BA, Scearce-Levie K, Lucas JJ et al. Increased vulnerability to cocaine in mice lacking the serotonin-1B receptor. Nature 1998;393: 175-78.
11. 11. Seevers MH, Deneau GA. Physiological aspects of tolerance and physical dependence. In: Root WS, Hofman FG, editors. Physiological pharmacology, vol. 1. New York: Academic Press; 1963, pp. 565-640.
12. 12. Kalivas PW, Stewart J. Dopamine transmission in the initiation and expression of drug-and stress-induced sensitization of motor activity. Brain Res Brain Res Rev 1991;16:223-44.
13. 13. Koob GF. Drugs of abuse: anatomy, pharmacology and function of reward pathways. Trends Pharmacol Sci 1992;13:177-84.
14. 14. Koob GF. Neural mechanisms of drug reinforcement. Ann NY Acad Sci 1992;654:171-91.
15. 15. Nestler EJ, Berhow MT, Brodkin, ES. Molecular mechanisms of drug addiction: adaptations in signal transduction pathways. Mol Psychiatry 1996;1:190-9.
16. 16. Nestler EJ. Molecular mechanisms of drug addiction. J Neurosci 1992;12:2439-50.
17. 17. Pennypacker KR, Zhang WQ, Ye H, Hong JS. Apomorphine induction of AP-1 DNA binding in the rat striatum after dopamine depletion. Brain Res Mol Brain Res 1992;15:151-5.
18. 18. Nye HE, Hope BT, Kelz MB, Iadarola M, Nestler EJ. Pharmacological studies of the regulation of chronic FOS-related antigen induction by cocaine in the striatum and nucleus accumbens. J Pharmacol Exp Ther 1995;275:1671-80.
19. 19. Nestler EJ. Molecular mechanisms of opiate and cocaine addiction. Curr Opin Neurobiol 1997;7:713-19.
20. 20. Hope B, Kosofsky B, Hyman SE, Nestler EJ. Regulation of immediate early gene expression and AP-1 binding in the rat nucleus accumbens by chronic cocaine. Proc Natl Acad Sci USA 1992;89:5764-8.
21. 21. Hope BT, Nye HE, Kelz MB et al. Induction of a long-lasting AP-1 complex composed of altered Fos-like proteins in brain by chronic cocaine and other chronic treatments. Neuron 1994;13: 1235-44.
22. 22. Self DW, Genova, LM, Hope BT, Barnhart WJ, Spencer JJ, Nestler EJ. Involvement of cAMP-dependent protein kinase in the nucleus accumbens in cocaine self-administration and relapse of cocaine-seeking behavior. J Neurosci 1998;18: 1848-59.
23. 23. Nakabeppu Y, Nathans D. The basic region of Fos mediates specific DNA binding. EMBO J 1989;8:3833-41.
24. 24. Fitzgerald LW, Ortiz J, Hamedani AG, Nestler EJ. Drugs of abuse and stress increase the expression of GluR1 and NMDAR1 glutamate receptor subunits in the rat ventral tegmental area: common adaptations among cross-sensitizing agents. J Neurosci 1996;16:274-82.
25. 25. Berhow MT, Hiroi N, Nestler EJ. Regulation of ERK (extracellular signal regulated kinase), part of the neurotrophin signal transduction cascade, in the rat mesolimbic dopamine system by chronic exposure to morphine or cocaine. J Neurosci 1996;16:4707-15.
26. 26. Berhow MT, Hiroi N, Kobierski LA, Hyman SE, Nestler EJ. Influence of cocaine on the JAK-STAT pathway in the mesolimbic dopamine system. J Neurosci 1996;16:8019-26.
27. 27. O'Callaghan JP. A potential role for altered protein phosphorylation in the mediation of developmental neurotoxicity. Neurotoxicology 1994;15:29-40.
28. 28. Da Cruz e Silva EF, O'Callaghan JP. Phosphoprotein phosphatases as potential mediators of neurotoxicity. In: Lowndes HE, Reuhl KR, editors. Comprehensive toxicology, vol. 11. New York: Pergamon; 1997, pp. 181-99.
29. 29. Walaas SI, Greengard P. DARPP-32, a dopamine-and adenosine 3′:5′-monophosphate-regulated phosphoprotein enriched in dopamine-innervated brain regions. I. Regional and cellular distribution in the rat brain. J. Neurosci 1984;4:84-98.
30. 30. Ouimet CC, Miller PE, Hemmings HCJ, Walaas SI, Greengard P. DARPP-32, a dopamine-and adenosine 3′:5′-monophosphate-regulated phosphoprotein enriched in dopamine-innervated brain regions. III. Immunocytochemical localization. J Neurosci 1984;4:111-24.
31. 31. Fienberg AA, Hiroi N, Mermelstein PG et al. DARPP-32: regulator of the efficacy of dopaminergic neurotransmission. Science 1998;281: 838-42.
32. 32. Nishi A, Snyder GL, Greengard P. Bidirectional regulation of DARPP-32 phosphorylation by dopamine. J Neurosci 1997;17:8147-55.
33. r 32 kDa)/protein phosphatase-1 pathway regulates dephosphorylation of the NMDA receptor. J Neurosci 1998;18:10297-303.
34. 34. Ricaurte GA, Schuster CR, Seiden LS. Long-term effects of repeated methylamphetamine administration on dopamine and serotonin neurons in the rat brain: a regional study. Brain Res 1980;193: 153-63.
35. 35. Hotchkiss AJ, Gibb JW. Long-term effects of multiple doses of methamphetamine on tryptophan hydroxylase and tyrosine hydroxylase activity in rat brain. J Pharmacol Exp Ther 1980;214:257-62.
36. 3H]cyanoimipramine autoradiography. Brain Res 1989;505:123-9.
37. 37. O'Dell SJ, Weihmuller FB, Marshall JF. Methamphetamine-induced dopamine overflow and injury to striatal dopamine terminals: attenuation by dopamine D1 or D2 antagonists. J Neurochem 1993;60:1792-9.
38. 38. Sonsalla PK, Gibb JW, Hanson GR. Roles of D1 and D2 dopamine receptor subtypes in mediating the methamphetamine-induced changes in monoamine systems. J Pharmacol Exp Ther 1986;238:932-7.
39. 39. O'Dell SJ, Weihmuller FB, McPherson RJ, Marshall JF. Excitotoxic striatal lesions protect against subsequent methamphetamine-induced dopamine depletions. J Pharmacol Exp Ther 1994;269: 1319-25.
40. 40. Girault JA, Walaas SI, Hemmings HCJ, Greengard P. DARPP-21, a cAMP-regulated phosphoprotein enriched in dopamine-innervated brain regions: tissue distribution and regulation of phosphorylation in rat brain. Neuroscience 1990;37:317-25.
41. 41. Pennypacker KR, Hong JS, McMillian MK. Pharmacological regulation of AP-1 transcription factor DNA binding activity. FASEB J 1994;8: 475-8.
42. 42. Pennypacker KR, Thai L, Hong JS, McMillian MK. Prolonged expression of AP-1 transcription factors in the rat hippocampus after systemic kainate treatment. J Neurosci 1994;14: 3998-4006.
43. 43. Pennypacker KR, Hong JS, McMillian MK. Implications of prolonged expression of Fos-related antigens. Trends Pharmacol Sci 1995;16:317-21.
44. 44. Pennypacker K. Transcription factors in brain injury. Histol Histopathol 1997;12:1125-33.
45. 45. Pennypacker K. AP-1 transcription factors: short-and long-term modulators of gene expression in the brain. Int Rev Neurobiol 1998;42:169-97.
46. 46. Zhang WQ, Pennypacker KR, Ye H et al. A 35 kDa Fos-related antigen is co-localized with substance P and dynorphin in striatal neurons. Brain Res 1992;577:312-17.
47. 47. Doucet JP, Nakabeppu Y, Bedard PJ et al. Chronic alterations in dopaminergic neurotransmission produce a persistent elevation of delta Fos B-Iike protein(s) in both the rodent and primate striatum. Eur J Neurosci 1996;8:365-81.
48. 48. Ridet JL, Malhotra SK, Privat A, Gage FH. Reactive astrocytes: cellular and molecular cues to biological function.Trends Neurosci 1997;20: 570-7.
49. 49. O'Callaghan JP, Miller DB, Imai H. Amphetamine and MPTP-induced damage to dopaminergic nerve terminals results in the transient expression of fos-related antigen (FRA-2). Soc Neurosci Abstr 1997;23:273.
50. 50. Campbell JS, Seger R, Graves JD, Graves LM, Jensen AM, Krebs EG. The MAP kinase cascade. Recent Prog Horm Res 1995;50:131-59.
51. 51. Gruda MC, Kovary K, Metz R, Bravo R. Regulation of Fra-1 and Fra-2 phosphorylation differs during the cell cycle of fibroblasts and phosphorylation in vitro by MAP kinase affects DNA binding activity. Oncogene 1994;9:2537-47.
52. 52. Herdegen T, Claret FX, Kallunki T et al. Lasting N-terminal phosphorylation of c-Jun and activation of c-Jun N-terminal kinases after neuronal injury. J Neurosci 1998;18:5124-35.
53. 53. O'Callaghan JP, Martin PM, Mass MJ. The MAP kinase cascade is activated prior to the induction of gliosis in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) model of dopaminergic neurotoxicity. Ann NY Acad Sci 1998;844:40-9.
54. 54. Kahn MA, Huang CJ, Caruso A et al. Ciliary neurotrophic factor activates JAK/Stat signal transduction cascade and induces transcriptional expression of glial fibrillary acidic protein in glial cells. J Neurochem 1997;68:1413-23.
55. 55. Berke JD, Paletzki RF, Aronson GJ, Hyman SE, Gerfen CR. A complex program of striatal gene expression induced by dopaminergic stimulation. J Neurosci 1998;18:5301-10.
56. 56. Greengard P, Nairn AC, Girault JA et al. The DARPP-32/Protein Phosphatase-1 cascade: a model for signal integration. Brain Res Rev 1998;26:274-84.